Israeli Life Science Industry Catalog

Government of Israel

Economic Missionto the West Coast

Israeli Life Science Industry CatalogBio International Convention 2016

Israeli Life Science Industry: A Source of InnovationIsraeli Pavilion Booth 2205, June 6-9, 2016

1 | P a g e

Israel: A Powerhouse of Opportunities

Over the last decade, Israel has introduced a wealth of

groundbreaking and valuable innovations in life sciences. Israel’s

life sciences sector is supported by a strong foundation of

academic excellence, including some of the world’s leading

research institutes, renowned R&D facilities and cutting-edge

medical centers. Bolstered by a highly skilled workforce, a

flourishing high-tech environment, and an entrepreneurial spirit,

Israeli companies have been joined by leading multinationals in

making Israel a recognized force in the industry worldwide. Global

giants, including Johnson & Johnson, Perrigo, GE Healthcare,

Phillips Medical, Abbott Laboratories, Merck Serono, Roche,

Takeda, Novartis, Monsanto , together with local companies such

as Teva - itself a multinational company - Given Imaging,

InSightec, Medinol and others have been continuously developing

and marketing life-changing medical breakthroughs and

innovations.

Prior to 1996, Israel was home to 186 life sciences companies. By

2015, this number had passed 1,300. With some 98 new

companies formed each year, 66% of all life sciences companies

operating in Israel today were established during the last ten

years. In a relatively short period of time, an impressive 34% of

these companies have already begun to generate revenue,

demonstrating that Israel has crossed the threshold from an

attractive start-up arena to a source of advanced, commercially

viable and promising businesses. The bridge connecting excellent

science to revenue-generating companies has been established.

As proof of the industry’s development, in 2014 life sciences

exports reached $8.5 billion, an increase of 10% over 2010. A rich

pipeline of seed companies promises to perpetuate current

growth.

Source: Invest in Israel & IATI

Why Israel?

Over 1,300 life sciences companies

Over 1/3 of LS start-ups already generate revenue

Source of numerous blockbuster drugs such as Copaxone and Rebif, generating over $5B in annual sales

Third in the world in innovation [World Economic Forum (WEF) 2015-16]

Life Sciences represent about 50% of Israeli civilian research activities (IATI 2015 report)

Pioneers in stem cell research and therapeutics

Extensive international R&D and commercial partnerships

World-renowned academic research institutes such as the Technion and the Weizmann Institute

Unique financing tools and incubator frameworks for start-ups

1.5% of the worldwide registered patents between 2010-2013 were Israeli (Central Bureau of Statistics)

2 | P a g e

Israel’s Competitive Edge Academia and Research Approximately 50% of all academic research funding in Israel is in the field of

life sciences, and institutions such as the Hebrew University of Jerusalem, Tel

Aviv University, Ben Gurion University of the Negev, the Technion - Israel

Institute of Technology and the Weizmann Institute of Science have played

dominant roles in advancing biotech R&D. In fact, over the past five years, the

Weizmann Institute was ranked twice as the top international academic

institution in the world for scientists to conduct research in life sciences. This

stems from impressive levels of R&D funding and highly skilled and creative

manpower, which continues to generate new patents in the field.

Cluster Effect

Many of Israel’s achievements in the life sciences sector stem from the fact

that over 90% of the population resides within two hours driving time of each

other and within close proximity to seven major universities and industrial

clusters. This cluster effect creates economies of scale, and allows for better

information sharing and synergies between the companies.

Entrepreneurial Spirit and Ingenuity

The exceptional volume of life science start-ups and patents attests to the

entrepreneurial and risk-taking climate in Israel. Israeli researchers and

entrepreneurs overcome technological barriers and solve development

problems within a short period of time and at a fraction of the cost of some of

their larger and more affluent competitors overseas.

Acquisitions of Israeli Life Sciences Companies 2005-2014 Since 2005, 62 Israeli life sciences companies have been acquired, whereby

the aggregate sum of these acquisitions was $7.7 billion excluding royalties.

Between 2013-2014 Israeli life sciences companies were acquired for almost

$2.9 billion (IATI report 2015).

Rapid Research to Financial Return

The last few years have witnessed several

significant Israeli life sciences “exit” transactions

with investors realizing impressive returns via IPOs,

mergers and acquisitions. Close to 60 life science

companies went public on the Tel Aviv Stock

Exchange (TASE) in recent years, among them

BiolineRx, Biondvax, Brainsway, Intec, Mazor,

Prolor, Pluristem, Hadasit Bio Holdings and Nasvax,

and approximately 15 Israeli companies have gone

public on foreign exchanges, mainly in the US. Source: Invest in Israel

3 | P a g e

Meet the Sponsoring Organizations

The sponsoring organizations of the Israeli delegation provide a full array of support and

services to nurture the development of industry and innovation:

The Israel Innovation Authority (formerly the Office of the

Chief Scientist & MATIMOP) is the main authority for

governmental support of technological innovation. The

Authority is Israel's central agency to manage the country’s

resource of innovation and is the Ministry of Economy &

Industry's operational arm in the arena of technological

innovation. The goal of the Authority is to provide

professional support and infrastructure to government

efforts to encourage and promote technological innovation,

complementing the major role that Israel already plays in the

global high-tech sector.

The Israel Advanced Technology Industries (IATI) is Israel’s

largest umbrella organization for companies, organizations,

and individuals in the high tech and life science sectors. In a

country like Israel where innovation is a national mindset,

IATI’s mission is to strengthen the Israeli high tech and life

science industries across the whole value chain and create

global, technological and innovational leadership.

The US-Israel Science and Technology Foundation supports

programs to create a seamless infrastructure for industry,

academia and government for the mutual benefit for the

economies of the US and Israel.

The Foreign Trade Administration at the Ministry of

Economy is responsible for managing and directing the

international trade policy of the State of Israel. The main

fields of activity include activities for the promotion of trade

and export, initiating and maintaining trade agreements for

the improvement of Israel’s trade conditions, attracting and

encouraging foreign investments and creating strategic

cooperation with foreign companies.

4 | P a g e

Meet the 2016 Bio Israeli Delegation

On behalf of the organizers and partners, we would like to introduce you to the 2016 Bio

Israeli Delegation. Twenty remarkable companies are attending, spanning the spectrum of

Israel’s vigorous life science community, from innovative start-ups to established companies.

Please take the time to explore their innovative solutions which you can find in this catalog.

We hope you will take the time to schedule a meeting with some of these companies and

see for yourself why Israel is driving innovation in the life sciences industry. You can visit the

Israel national pavilion at Booth 2205.

Additionally, most of the Israeli companies are participating in the Bio Business Forum

one-on-one partnering service, and you can find them in the online system at:

http://convention.bio.org/partner/

http://convention.bio.org/partner/

5 | P a g e

Company Name Page

BMR Solutions 7

BrainMARC 8

BrainStorm Cell Therapeutics

9

Can-Fite BioPharma Ltd. 10

ChroniSense Medical 11

Compugen Ltd. 12

DALI Medical Devices 13

Immune System Key 14

Kadimastem 15

Israeli Company Profiles

6 | P a g e

Mybiotics 16

NovellusDx 17

Nucleix 18

Nurami 19

Optical Imaging 20

Oramed 21

PamBio 22

PolyPid 23

Raziel Therapeutics 24

Taliaz Diagnostics 25

VBL Therapeutics 26

7 | P a g e

Company Profile:

BMR Solutions is a privately held Israeli

biopharmaceutical startup company with a

pipeline of small molecule drugs in late pre-

clinical stages, addressing age related diseases

and cancer supportive care in elderly patients.

Based on the proprietary discovery of the

BMRH platform, we do endogenous

stimulation of adult stem cells. Our objective

is to develop and commercialize BMRH stem

cells modulators, for improvement of self-

regenerative capacity of the body.

Technology Description:

Our drugs were discovered in animal source as

a part of four decades of research aimed at

investigation of radio-protective mechanisms

existing in animals and discovery of drugs which cause bone marrow recovery following

deadly irradiation. During this screening research one of the vertebrate animal species was

found to be extremely radio-resistant, about 100 - fold more resistant than humans. Specific

molecules from that animal, which are responsible for stimulation of adult stem cells (stem

cells modulators) have been discovered, characterized and synthetically produced. These

molecules augment recovery of bone marrow and blood and, therefore, induce survival and

recovery of the whole organism after high doses of chemotherapy, irradiation and after age

related damages.

BMR Solutions revealed the importance and the clinical relevance of BMRH family of

synthetic stem cell modulators in thousands of animals in several disease and aging models.

We created a broad pipeline addressing various clinical needs. Our business model includes

collaborations surrounding particular drug candidates for development, strategic

partnership and commercialization.

Company Name: BMR Solutions

Contact Details

Address: 49 Sokolov st, Herzeliya, ISRAEL

Phone: 972-54-5696682

Fax: 972-3-5492874

Email: [email protected]

Website: www.bmrsolutions.co.il

Exhibition Representatives

Name: Ronen Kahana

E-mail: [email protected]

Category: Biopharmaceutical Company

mailto:[email protected]

http://www.bmrsolutions.co.il/

8 | P a g e

Company Profile:

BrainMARC has developed a breakthrough

mobile health platform for monitoring mental

activity. Its’ easy-to-use tool derives proven

and robust biomarkers sampled from two (dry)

EEG electrodes. BrainMARC’s biomarkers are

applicable to a wide spectrum of

neuropsychiatric syndromes where they can

enhance therapeutic protocols, predict clinical

dynamics, and promote general wellness. They

are also suitable for non-medical and research

applications.


BrainMARC’s platform is based on advanced

analysis technology, providing precise and

easy-to-generate electrophysiological markers for tracking neuropsychological status. The

process is significantly easier than existing EEG-based technologies because only a minimal

number of electrodes is needed (Shahaf and Pratt. 2013, Shahaf et al., 2015) and the target

markers can be extracted from a very short sample. In addition, emotion parameters can be

detected even when the user is active.

BrainMARC's Mental Health monitor is a wearable device for continuous use during daytime

routines. For example, a child with ADHD can wear the device while doing homework to

support effective task planning and performance. The device can also significantly enhance

the effectiveness of cognitive behavioral therapy (CBT) for mental health disorders such as

anxiety, depression, etc. Clinical studies have also demonstrated its potential to dramatically

improve post-stroke rehabilitation treatments.

BrainMARC's Mental Health prediction technology is based on the same wearable device.

However, it is designed to be used on a daily basis for a short (1-5 minute) EEG

measurement session in order to provide an objective neurophysiological measure of the

user’s current condition as well as an indication of immanent clinical dynamics. Used in

conjunction with a mobile app, it can, for example, predict the attention level of an ADHD

subject over the next few hours; the probability of a migraine attack within the next 1-2

days; or, in the case of depression, the efficacy of a specific treatment as well as the

potential for deterioration over the coming weeks.

Company Name: BrainMARC Ltd.

Contact Details

Address: Beit Hermon, Yokneam Illit,

P.O. Box 128, 20692, Israel

Phone: +972-4-666-0677

Fax: +972-4-643-2998


Website: http://brainmarc.com/

Exhibition Representative

Name: Dr. Yael Rozen


Category: Digital health

9 | P a g e

Company Profile:

Brainstorm Cell Therapeutics (Nasdaq: BCLI) is

a biotechnology company developing novel

adult stem cell therapies for debilitating

neurodegenerative disorders such as

Amyotrophic Lateral Sclerosis (ALS) and

Multiple Sclerosis among others. These

diseases for the most part have no or limited

treatment options and as such represent

unmet medical needs. We believe that

NurOwn®, our proprietary process for the

propagation of Mesenchymal Stem Cells and

their differentiation into neurotrophic factor

secreting cells and their transplantation at, or

near, the site of damage, offers the hope of

more effectively treating neurodegenerative

diseases.

NurOwn® is in clinical development for the

treatment of ALS. It has been granted Fast

Track designation by the FDA for this indication, and has been granted Orphan Status in both

the United States and in Europe. Brainstorm has completed two clinical trials of NurOwn® in

patients with ALS in Israel. The results of both studies, recently published in JAMA Neurology

(January 2016), showed the treatment was safe and well tolerated and provided indications

of possible clinical benefits on both the ALS Functional Rating Score (ALSFRS-R) and Forced

Vital Capacity (FVC).

Brainstorm is completing a double blind placebo controlled Phase II clinical trial for ALS

patients at three leading US medical centres: Mass. General and UMass hospitals in Boston

and at the Mayo Clinic in Rochester (MN). Additionally, a multi-dose study of NurOwn® for

ALS in Israel is scheduled for 2016. An additional Phase I/II clinical study for other

neurological disorders is also in preparation.


Bone marrow cells are harvested from the

patient, and Mesenchymal Stromal stem

cells (MSC) are isolated and expanded in

culture. Using the company's core cell

differentiation technology, the MSC are

then induced to differentiate into MSC-NTF

cells (Mesenchymal Stromal Cells-secreting

Neurotrophic Factor) and transplanted back

into the patient at or near the site of

damage.

Company Name: Brainstorm Cell Therapeutics Ltd. Technology Sector: Biotechnology / Cell Therapy / Regenerative Medicine Company Stage: Clinical stage Traded on NASAQ: BCLI Contact Details 12 Bazel Street POB 10019 Kiryat Aryeh Petach Tikva, Israel 4900101 Phone: +972-3-9236384 Fax: +972-3-9236385 Website: www.brainstorm-cell.com Representative Name: Chaim Lebovits President & CEO E-mail: [email protected]

http://www.nasdaq.com/symbol/bcli/real-time

tel:201-488-0460

http://www.brainstorm-cell.com/

10 | P a g e

Company Profile:

Can-Fite BioPharma Ltd. (NYSE MKT: CANF) is

an advanced clinical stage drug development

company with 3 small molecule drug candidates

in its pipeline for the treatment of cancer,

inflammatory diseases, and sexual dysfunction.


Can-Fite’s platform technology is based on the

finding that the Gi protein-coupled A3

adenosine receptor (A3AR) is over-expressed in

inflammatory and cancer cells. The Company’s

proprietary compounds target and bind with

A3AR and induce specific cell death of cancer

and inflammatory cells. This creates a targeted

anti-cancer and anti-inflammatory effect, while

leaving normal cells unharmed. A3AR is also a

biological predictive marker which helps to

identify individual patients' responsiveness to the Company’s drugs.

CF101 – Arthritis & Psoriasis Ready to Enter Phase III Can-Fite’s 12-week Phase IIb study of

CF101 for the treatment of rheumatoid arthritis included 79 patients. The data showed

CF101 met all primary efficacy endpoints with statistically significant superiority over

placebo in reducing signs and symptoms of rheumatoid arthritis as compared to the placebo.

Psoriasis Phase II/III Study Showed Positive Data, with over 300 patients with moderate to

severe psoriasis suggest CF101 as a potential first-line systemic therapy. Although the study

did not meet its primary endpoint of efficacy at week 12, it showed a statistically significant

and cumulative improvement in efficacy during weeks 16-32. Can-Fite plans to initiate its

Phase III trials in 2016 for both indications.

CF102 - Cancer Drug in Phase II with Fast Track & Orphan Drug Designations The U.S. FDA

granted Can-Fite Fast Track Designation for CF102 as a second line treatment for HCC in

patients who have previously received Nexavar (sorafenib). CF102 has Orphan Drug

Designation in both the U.S. and EU for the treatment of HCC, the most common type of

liver cancer. Can-Fite is currently conducting a Phase II study of CF102 for the treatment of

advanced HCC which is expected to have 78 patients enrolled in the U.S., Europe and Israel.

The drug is also developed for the NASH indication with a Phase II underway.

CF602 - Sexual Dysfunction Drug May Offer Effective, Safer Alternative In preclinical

studies, subjects treated with CF602 showed a 118% improvement in erectile function

measures as compared to placebo. This result is similar to that achieved by Viagra in

preclinical studies. Can-Fite is conducting a full preclinical program for CF602 in preparation

for filing an IND with the U.S. FDA for the indication of sexual dysfunction and submitting a

Phase I protocol to an IRB in Q4 2016.

Company Name: Can-Fite BioPharma

Contact Details

Address: 10 Bareket st. Kiryat Matalon

Phone: +972-3-9241114

Fax: +972-3-9249378


Website: www.canfite.com


Name: Dr. Sari Fishman


Category:

Cancer, Autoimmune & Liver Diseases,

Sexual Dysfunction

11 | P a g e

Company Profile:

ChroniSense Medical is a young startup

developing wearable health monitoring products

for patient use. ChroniSense is focused on

medical-grade, regulatory cleared standards of

sensing and processing physiological data. Our

products are designed to improve the quality of

life of the chronically ill by reducing dependence

on the clinic and bedside monitors. Our group

brings unique multidisciplinary expertise from

engineering, computer programming,

physiology, psychology, mathematics, and

biostatistics to the R&D process. We are based in

Yokneam Science Park, Israel, and are a member

of the Rainbow Medical Group.


ChroniSense’s main product platform is a

clinical-quality, wrist-wearable medical device. The device incorporates several

breakthrough technologies in medical sensing, and is currently at an advanced R&D stage,

nearly ready for clinical evaluation. Our device includes multiple ultra-sensitive biosensors,

combined with specialized algorithms for estimation of a range of clinical indices like pulse

and respiration rates, blood pressure, electrocardiogram, oxygen saturation, cardiac output,

and more. The system communicates, via Bluetooth LE, with software on a smartphone or

PC; basic analysis is done on the wrist along with basic alerts; advanced analysis and long-

term data storage are performed on the PC/smartphone platforms, with Internet

communications/storage capability.

Such continuous mobile medical monitoring has the potential to greatly benefit chronic

disease sufferers, not only by detecting acute distress episodes, but by tracking

deterioration or improvement with ongoing treatment. Patients would no longer be

restricted to bed or clinic. Alerts and evaluations can be sent to health care providers in real

time, providing round the clock medical security for those who most need it. No other

product is available for such multi-parameter long-term medical follow-up of chronically ill

patients while allowing an active, normal life.

Company Name: ChroniSense Medical

Contact Details

Address: Hamada Street 2, POB 684,

Yokneam 2069202, Israel

Phone: +972-4-8275103

Fax: +972-4-8275102


Website: www.chronisense.com


Name: Danny Lange


Name: Elliot Sprecher


Category: Wearable Medical Devices

http://www.chronisense.com/

12 | P a g e

Company Profile:

Compugen is a therapeutic discovery company

with a unique, broadly applicable, predictive

discovery infrastructure, which is advancing its

therapeutic pipeline consisting mainly of early-

stage immuno-oncology programs, aimed at

harnessing the immune system to eradicate

cancer. The company is headquartered in Israel

with R&D facilities in Israel and South San

Francisco .

Our pipeline is based on novel Compugen-

discovered drug targets, primarily immune

checkpoint candidates that are predicted to

provide cancer immunotherapies addressing

unmet cancer types and patient populations, both as monotherapy and as combination

therapy. The Company is working on several exciting novel immune checkpoint programs,

including CGEN-15029, its highest priority internal mAb program which we plan to advance

towards clinical trials.

CGEN-15001 is our lead program for autoimmune diseases. CGEN-15001 is an Fc fusion

protein that contains the extracellular domain of CGEN-15001T, a novel immune checkpoint

discovered by Compugen. CGEN-15001 was shown to inhibit activation of T-cells and to

restore immune balance and has the potential to address multiple autoimmune disease

indications.

The Company’s second discovery program is focused on targets for antibody drug conjugate

(ADC) therapy. Our lead ADC program, CGEN -15027, has demonstrated high expression

levels in lung, ovarian, and pancreatic tumors and cancer killing activity in-vitro, highlighting

its potential as a target for ADC therapy.

Compugen’s business model is based on selectively entering into collaborations for its novel

target candidates and drug product candidates at various stages of research and

development under revenue-sharing agreements. We are currently developing antibody-

based cancer immunotherapies in collaboration with Bayer Healthcare (CGEN-15001T and

CGEN-15022) and have established a joint venture with Merck Serono, Neviah Genomics,

focused on the discovery and development of novel biomarkers for drug toxicity.

Company Name: Compugen Ltd.

Contact Details

Address: 26 Harokmim Street,

Building D Holon 5885800, Israel

Phone: +972-3-7658-585

Fax: +972-2 3-7658-555


Website:www.cgen.com


Name: Tsipi Keren Lehrer



http://www.cgen.com/

13 | P a g e

Company Name: DALI Medical Devices

Contact Details:

6 Nahal Harif St.

P.O. Box 13223

Yavne 8122503, Israel

Phone: +972-8-3730080

Fax: +972-8-8585857


Website: www.dalimed.com


Name: David Daily, CEO & Co-Founder


Categories

Medical Devices, Drug Delivery Devices

Company Profile:

DALI Medical Devices (DALI) was founded in

2003 by a team with more than 15 years of

experience in developing innovative drug

delivery devices for the pharmaceutical

industry.

DALI has developed a family of innovative

autoinjectors (in collaboration with Elcam Drug

Delivery Devices (E3D)) to improve patient

compliance and contribute to treatment

success. Some of these autoinjectors have

received FDA clearance and some have been

selected by major pharma companies.

Leveraging its expertise, DALI is developing a

proprietary new line of safe, easy autoinjectors:

Innovative Safe Auto-Needles (SANs) address unmet needs we identified in the growing

injectable drug-delivery arena.

DALI seeks pharmaceutical, financial, and other strategic partners to bring our unique SANs

to market.

The Technology:

The proprietary SAN product family has been designed for improved patient compliance and

adherence to treatment: All SANs reduce needle phobia, anxiety and pain perception by

hiding the needle, ensuring consistent needle penetration depth and angle, preventing

needlestick injuries, and allowing for user-controlled injection speed for increased comfort.

The unique SANs can be customized for use with all types of syringes, vials and cartridges.

Pipeline technologies: (1) A bolus / large volume injection; and (2) A novel injector for

minimally invasive delivery of therapeutics to the posterior eye (Cooperation with Sheba

Medical Center, Israel).

http://www.dalimed.com/

14 | P a g e

Company Profile:

ISK is a privately held company, engaged in

discovery and development of innovative

treatments for malignant and autoimmune

diseases with strong unmet needs. Its assets

are based on novel human secreted peptides,

which were discovered by the founders.


ISK’s lead compound is Nerofe. Nerofe was

granted by the FDA with orphan drug status

for AML treatment.

ISK Ltd has completed phase I clinical trial with

Nerofe in cancer patients with progressive

disease. Nerofe is highly safe in humans – no

toxic effects were seen during the trial. Nerofe

is stable in the human blood.

Nerofe is the first highly safe anti-cancer agent

that affects all 3 biological processes that affect cancer progression: Angiogenesis, Cancer

Immunotherapy and Cancer cells proliferation.

In phase I we have clearly seen:

1. Induction of strong anti-angiogenic effect.

2. Activation of anti-cancer immune response.

3. In vitro experiments show that Nerofe has direct strong inhibitory effect on cancer cell

proliferation.

Nerofe's mode of action is through ER-stress mediated by a strong induction of BIP as seen

in-vitro, in-vivo and in the human trial. BIP serum levels change after only two weeks of

Nerofe treatment can help predict the success of the treatment.

We have developed a novel marker whose presence in patient’s biopsy can predict success

of treatment with Nerofe. Patients whose tumor biopsy was positive for the marker stayed

in the trial for 6 month or longer with a Stable Disease.

The company’s main interest is to treat AML, pancreatic and TN breast cancer patients.

Company Name: Immune System Key

LTD.

Contact Details

Address: Hava'ad Haleumi 21, Jerusalem

91160, Israel

Phone: +972-26751189

Fax: +972-26751179


Website: http://www.immunesk.com/


Name: Joel Ohana


Category: Biotechnology/Cancer


http://www.immunesk.com/

15 | P a g e

Company Profile:

Kadimastem (TASE: KDST) develops stem cell

based therapeutics for degenerative diseases

of the nervous system and diabetes. The

company’s technological platform enables the

differentiation of stem cells into a range of

functional human cells, including pancreatic

cells that produce and secrete insulin as well

as neuron-supporting cells of the brain. These

functional cells are used for regenerative

medicine to treat neurodegenerative diseases

and diabetes.

Kadimastem relies on technology that was

initially developed at the Weizmann Institute

in Prof. Michel Revel’s laboratory and which is

now being further developed in the company’s

labs in the Weizmann Science Park, Nes Ziona,

Israel. The company's technologies are

protected by patents and patent applications. Kadimastem specializes in generating

functional human cells from human pluripotent stem cells (hPSC). hPSCs can be expanded

indefinitely, allowing industrial scale production under GMP conditions.


ALS: Multiple studies have demonstrated that brain supporting cells, mainly astrocytes, play

a crucial role in ALS disease progression. In ALS patients the astrocytes were found to be

malfunctioning and to attack the neurons. Kadimastem’s healthy human astrocytes that are

derived from hPSC will be used to compensate for the malfunctioning cells in ALS patients.

Kadimastem’s therapy will be a frozen shelf product containing cells that when thawed will

be administered directly into the patient’s spinal cord fluid by a standard intrathecal

injection under local anesthesia. Following successful development of the ALS treatment,

the company expects to expand the treatment to additional neurodegenerative indications.

Diabetes: The company's solution is based on stepwise differentiation of hPSC towards

pancreatic islet-like clusters, producing functional insulin (beta cells), glucagon (alpha cells)

and other hormones. Starting from large scale hPSC cultures, Kadimastem's process drives

the cells through several condition changes towards pancreatic endocrine cells. These

functional hormone producing cell aggregates will be encapsulated to prevent immune

rejection and mobility in the patient body, while allowing glucose sensing and insulin

secretion. Kadimastem’s therapy will be a shelf product containing cells that, once thawed,

will be administered subcutaneously (under the skin) by a standard injection under local

anesthesia.

Company Name: Kadimastem Ltd.

Contact Details

Address: 7 Sapir St., Nes Ziona, Israel

Phone: +972-73-7971601

Fax: +972-8-9100698


Website: www.kadimastem.com


Name: Yossi Ben Yosef, CEO

E-mail: : [email protected]

Category: Biotechnology; Cell Therapy; Stem Cells Neurodegenerative Diseases, ALS; Metabolic Diseases; Diabetes

16 | P a g e

Company Profile:

Mybiotics pharma is a life science startup

company, founded in 2013 in Israel. Mybiotics

develops novel Microbiome Pharmaceuticals.

Based on its proprietary Mycrobe delivery

technology, the company develops bacteria-

based products for treatment of microbiome

related diseases including C. difficle infection

and Antibiotic associated diarrhea prevention.


Delivery Technology

Mycrobe technology solves one of the major

challenges in the probiotic market today: The

delivery of live and colonizing bacteria to the

digestive tract.

Probiotics grown in Mycrobe technology:

1. Survive the acid conditions of the stomach without being enterically coated

2. Colonize the digestive tract thus inducing a substantial and long-lasting effect on the

digestive bacterial community and whole body health.

Whole microbiome transplantation:

Based on the Mycrobe technology, Mybiotics’ whole microbiome tranplantation consists of a

whole microbiome community compromising 70-90% of healthy donor bacteria grown in

laboratory conditions. This product will replace fecal transplantations (FMTs) that are

currently being used for curing recurrent C. difficle infections and potentially other

microbiome related diseases.

Company Name: Mybiotics

Contact Details

Address: Golda Meir 5, P.O 4061, Ness

Ziona 7414001, Israel

Phone: 972-8-6118286

Fax: 972-9-7770250


Website: www.mybiotix.com


Name: Didi Daboush


Category:

17 | P a g e

Company Profile:

NovellusDx tailors actionable treatment for

cancer patients. Combining a highly

experienced team, cutting-edge technology,

and a propriety service, NovellusDx generates

an array of live cells expressing patient genes,

and monitors their pathway activity, cross-talk

between genes and response to drugs and

drugs combination. NovellusDx delivers

Functional Annotation for Cancer Treatment

system (FACT).

Acting in the untapped, ~$15B market of

oncology diagnosis, NovellusDx is collaborating

with over a dozen leading medical centers to

deliver evidence-based treatment to each

patient. The FACT system also helps biopharma

companies identify subgroups of cancer patients likely to respond to existing therapies,

stratify patients to enable more efficient trials and isolate new target mutations.

Current Achievements:

International and NY state CLIA certified Lab

Dozens of case studies showing added value to NGS

Collaborations with leading medical centers worldwide such as

Massachusetts General Hospital, Mayo Clinic and MOFFITT

Operational service lab opening mid 2016

IVD product core technology POC


Overview of the process:

1) Patient mutations are reproduced based on biopsy-derived NGS information (E-

patients)

2) Personalized chip is printed with the patient oncogene. The genes are expressed in live

cells

3) The chip is scanned through a high-content automated microscopy system, and the

oncogenic activity level associated with each specific gene, as well as cross-talk

between genes, is determined

4) The information is presented as a map of the signaling pathways superimposed with all

relevant clinical information

NovellusDx reports the signaling pathway activity in the presence of the patient’s mutated

genes and their response to a battery of drugs and drug combinations.

Company Name: NovellusDx

Contact Details

Address: Jerusalem Bio-Park. Hadassah

Medical Center Campus, Jerusalem

Phone: +972(02)5001100

Fax: +972(02)5477099


Website: www.novellusdx.com


Name: Dr. Revital Sharivkin


Category: Personalized Medicine

18 | P a g e

Company Profile:

Nucleix Ltd. develops, manufactures and

markets innovative non-invasive molecular

cancer diagnostic tests. Our highly sensitive and

specific tests are based on identification of

subtle changes in methylation patterns. Nucleix

technology is based on a combination of a new

biochemical platform in conjunction with

sophisticated algorithms.

Our first product Bladder EpiCheck® is a urine

test for monitoring of bladder cancer, and

includes a panel of 15 proprietary biomarkers

that are multiplexed in a real-time PCR analysis.

This test has shown 90% sensitivity, 83%

specificity and 97% NPV (based on a cohort of

221 patients that were monitored for

recurrence by Prof. Ilan Leibovitch at Meir

Medical Center in Israel) and it is expected to

reach the market during 2016.

Nucleix pipeline includes diagnostic tests for lung and colorectal cancer detection from

blood samples, using its proprietary and highly innovative technology. Nucleix is backed up

by leading investors including OrbiMed - the world’s largest bio-medical VC funds.


Methylation of the DNA is a set of ‘switches’ that activate or deactivate specific genes in

order to allow different cell types to perform their role. It is therefore a powerful tool to

distinguish between cell types. Cancer cells show changes in methylation pattern in relation

to healthy cells, and if one could “read” these methylation changes against a large

background of normal signal coming from healthy cells, one would be able to detect the

presence of tumors in body fluids, such as urine and blood. Nucleix technology is based on

our two platforms:

Bioinformatics tool - enabling rapid and systematic discovery and development of

biomarker panels for a wide range of clinical tasks, based on sophisticated

algorithms.

Biochemical tool – a proprietary technology for a simple, low cost clinical assay with

a biochemical sensitivity that is better than 1:150,000 (that is identifying one

methylation change in a background of 150,000 normal molecules).

The above tools enable Nucleix to develop highly sensitive and specific cancer diagnostic

tests as proved by our first product Bladder EpiCheck – a urine test for bladder cancer

detection and monitoring (Bladder EpiCheck is not approved for clinical use)

Company Name: Nucleix Ltd.

Contact Details

Address: 3 Pekeris St. Rehovot 7670203

Israel

Phone: +972-8-9161616

Fax: +972-89166966


Website: www.nucleix.com


Name: Arnon Horev


Category: Cancer Diagnostics

19 | P a g e

Company Profile:

Nurami Medical Ltd. is a medical device

company with a revolutionary, proprietary

nanofiber and sealant technology focused on

the soft tissue repair market, which is worth

$10 billion globally. With its ability to produce

highly flexible, durable and multi-functional

patches that seal undesired leakages and

enhance tissue-regeneration, Nurami Medical

is positioned at the forefront of next-

generation surgery. Nurami's first product is a

dural substitute patch for neurosurgeries.

Nurami is conducting advanced pre-clinical

trials and plans to initiate clinical trials by the

end of 2016.


Nurami developed ArtiFascia® a revolutionary nanotechnology solution that address a

problem inherent to many current soft tissue reconstruction products. ArtiFascia® is an

innovative porous patch made of synthetic medical-grade biodegradable nanofibers

combined with a special deformable sealant embedded in the patch itself. The nanofibers

promote tissue regeneration whereas the sealant prevents leakage. First product is a Dural

substitute for neurosurgery. Lung surgery, colo-rectal anastomosis are products in

development. Nurami is at advance pre-clinical stage and plans to start first in human trials

for the neurosurgery application by the end of 2016.

Company Name: Nurami Medical LTD

Contact Details

Address: Nazareth, Israel

Phone: +972-54-4487-673

Fax: +972-4-656 4129


Website: Nurami-medical.com


Name: Dr Amir Bahar


Category:

Regenerative implantable medical

device

20 | P a g e

Company Profile:

Today, Optical Imaging Ltd. (OI) develops,

manufactures and sells its proprietary

breakthrough functional and multi-modal

imaging system into the ophthalmology &

neurology markets. Looking forward, the

company intends to expand applications into

systemic diseases – targeting cardiology and

vascular diseases – a market that is ripe for

an easy-to-use, versatile imaging system for

the diagnosis and management of systemic

diseases. The company’s imaging systems

address multi-billion dollar markets. Optical

Imaging’s vision is to provide clinicians with a

multi-modal, functional, non-invasive retinal

imaging platform to improve diagnosis and treatment monitoring, starting with

ophthalmology and neurology and then expanding the platform to other organs of the body

-- through the eye and directly. Because the eye truly is a window, it can enable the

assessment, diagnosis and management for many systemic diseases: (1) Neurological

diseases, including Alzheimer’s & Multiple Sclerosis; (2) Blinding Conditions like Diabetic

Retinopathy, AMD & Glaucoma; (3) Cardiovascular diseases and risk assessment of stroke.

The founder & chief scientist, Prof. Amiram Grinvald from the Weizmann institute, won the

Dan David Prize for the innovative research & development of optical imaging.


Optical Imaging’s multi-modal, functional, non-invasive retinal imaging system can provide

the clinician with missing information of tissue/organ functional parameters by means of

comparative processing of consecutive images taken in a form of a short movie. The unique

nature of this technology is based on its proprietary data acquisition protocols and image

processing algorithms, enabling the comparative analysis of the different information

retrieved from the consecutive images that contain very small optical changes associated

with metabolic processes. Hence, this technology literally enables one to “see the invisible”,

e.g. the movement of red blood cells through blood vessels of the retina, the brain or other

tissue. The technology provides a quantitative functional mapping of four innovative vital

indices: (i) visualization of “invisible capillaries” for diagnostic purposes, follow-up and

enhanced treatment of neovascularization (related to degeneration & cancer diseases); (ii)

Non-invasive and precise quantification of the velocity of blood flow within the capillary bed,

as well as in secondary and tertiary small blood vessels (as related to Atherosclerosis); (iii)

Measuring oxygen saturation non-invasively, serving as a major breakthrough in diagnosis

and topographically directed treatment of retinal, brain and cardiovascular diseases; and (iv)

Imaging of metabolic and electrical activities. Conventional parameters provided by the 60

year-old gold standard can also be measured.

Company Name: Optical Imaging Ltd.

Contact Details

Address: Rehovot, Israel

Phone: +972-8-9463259

Fax: +972-8-9463261


Website: www.opt-imaging.com


Name: Sagi Reuven


Category: Medical Device

21 | P a g e

Company Profile:

Oramed Pharmaceuticals (NASDAQ: ORMP) has

developed an innovative technology to transform

injectable treatments into oral therapies.

Oramed’s flagship product, an oral insulin

capsule, has the potential to better the lives of

millions of diabetics around the world – allowing,

amongst other things, type 2 patients to begin

insulin therapy earlier without fear of needles.

Oramed’s oral insulin is currently in advanced

clinical trials under the US FDA for both type 1

and type 2 diabetes.

In addition to oral insulin, the company’s

proprietary POD™ (Protein Oral Delivery)

technology can be used to orally administer a

number of protein-based therapies, which are

available only via injection.


Oramed’s POD™ technology has been designed to protect orally delivered proteins from

detrimental enzymatic activity within the gastrointestinal tract and to enhance their

absorption across the intestinal wall.

The active protein is protected within a capsule that features a highly protective coating as

well as specialized protease inhibitors.

Drug availability is further secured by an absorption enhancer that facilitates protein passing

across the intestinal barrier.

Company Name:

Oramed Pharmaceuticals

Contact Details

Address: Hi-Tech Park 2/4 Givat Ram

Jerusalem

US Phone: +1-718-831-2512

Phone: 972-2-566-0001

Fax: 972-2-566-0004


Website: www.oramed.com


Name: Nadav Kidron


Category: Pharmaceutical


http://www.oramed.com/


22 | P a g e

Company Profile:

PamBio is an innovative, pre-clinical stage

biotechnology company developing drug

therapy for acute bleeding conditions and

specifically for the treatment of intracranial

hemorrhage (ICH, stroke). There is an unmet

need for a safe and effective treatment for

acute bleeding conditions, with no current

treatment for ICH. ICH accounts for about 10-

15% of all strokes. There are approximately

100,000 new ICH cases per year in the US. The

death rates after an ICH are about 31% at the

first 7 days and 59% at one year, and many

patients who survive are left disabled.

According to the internet stroke center, the

estimated lifetime cost for a new case of ICH is

US$ 123,565. This translates to US$ 8-9 Billion

dollars cost to society to treat ICH new cases

each year.


Our drug product in development is an inactive recombinant mutant-tPA protein. Its S481A

amino acid substitution renders the protein catalytically inactive but maintains its structure

and ability to interact with major components of the fibrinolytic pathway. This tPA-S481A

therapeutic biomolecule has a dual, anti-fibrinolysis and neuroprotective effect:

A. Blocking of both tPA and uPA fibrinolysis enzymes’ activity, which makes it currently

the only anti-bleeding agent available for treatment in a time-window of beyond 3 hours

B. Limiting tPA and glutamate mediated neurotoxicity and providing neuroprotection,

by blocking the binding of tPA to NMDA receptors

PamBio’s mutant-tPA proposed drug benefits include:

Stabilizing blood clots (in contrast to creating blood clots) and preventing bleeding

Increasing the anti-bleeding treatment time-window to beyond 3 hours

Minimizing blood toxicity in the brain, by preventing bleeding

Preventing NMDA-receptor-mediated excitotoxic neuronal death – a

neuroprotection effect

A high degree of similarity to human protein that minimizes potential

immunogenicity and organ/tissue toxicity

A high target specificity for reduced side effects

A high affinity binding to targets to minimize dose

A unique and safe mechanism of action

A short half-life

Company Name: Pam-Bio Ltd.

Contact Details

Address: P.O. Box 1252,Nazareth Illit

17111, Israel

Phone: +972-4-6098606

Fax: +972-4-6564129


Website:

http://www.ngt3vc.com/pambio-

innovating


Name: Amos Ofer, PhD, MBA - CEO


Category: Biotechnology and pharma

23 | P a g e

Company Profile:

PolyPid is an emerging clinical stage specialty

pharmaceutical company focused on clinical and

commercial development of products based on a

proprietary platform, PLEX™ (Polymer-Lipid

Encapsulation matriX). It operates in the field of

extended release, local drug delivery where

current local or systemic administration has

limited effect, is too toxic, or both. Our business

model combines both the development of our

proprietary pipeline together with collaboration

with other companies to support the

development of their novel drugs by the PLEX

technology. On our proprietary pipeline arm we

are focused on infection treatment and

prevention, an increasing global health concern,

accounting for 99,000 deaths in the US alone

every year. This way, we mainly target the

Surgical Site Infections (SSIs), the second most

prevalent type of Healthcare Acquired Infections (HAIs). SSIs have substantial negative

impact on patients’ clinical outcomes, is the most common reason for unplanned

readmission and therefore poses a significant healthcare system burden. PLEX™ efficacy was

demonstrated clinically in osseous tissues using BonyPid-1000™. BonyPid-1000™ is a PLEX™

based product that contains a powerful antibiotic and it is combined with bone graft

substitute, intended for supporting an antibacterial secured bone healing process in

contaminated sites. BonyPid-1000™ has completed a clinical trial in severe open fractures

indication, demonstrating excellent safety and efficacy results, including 0% infections in the

target fracture and 0% amputations after 6-12 months follow up (vs. average of 25% and 7%,

respectively in historical control group with the same severity and from the same hospital).

BonyPid-1000 is currently in the pivotal trial stage and is expected to gain market approval in

2017.


The PLEX™ platform is a matrix made of thousands of layers of polymers and lipids that

entrap a therapeutic drug, thus enabling an effective pre-determined, controlled, constant

and considerably prolonged localized drug delivery inside the body.

Demonstrated to fit all drugs sizes and characteristics i.e. many drugs can be used, including small molecules, peptides, proteins and nucleic acids

Prolonged duration - Days >>Weeks >> Months, pre-programmed as needed

Protected drug reservoir - protection from in vivo hydration and enzymatic degradation over the needed extended period

Constant and controlled release rate, pre-programmed as needed

Versatile solutions – multiple drug combinations can be used

No chemical bonds are formed between the drug and the formulation compounds

Administration – pure structures as well as coating of medical devices

Company Name: PolyPid

Contact Details

Address: 18 Hasivim st., Petach-

Tikva, Israel

Phone: +972-747195700

Fax: +972-747195718


Website: www.polypid.com

Exhibition Representatives Name: Amir Weisberg E-mail: [email protected]

Name: Noam Emanuel Email: [email protected] Name: Dan Popovic Email: [email protected] Category: Drug Delivery



24 | P a g e

Company Profile:

Raziel Therapeutics is a clinical-stage

pharmaceutical company developing a

proprietary drug (NCE) that after a single

injection into subcutaneous fat, converts

white adipose tissue (WAT) into

thermogenic, brown-like adipose tissue.

Raziel’s prime-candidate, RZL-012, is a first-

in-class, currently in clinical development

to treat obesity and related disorders.

Raziel launched its clinical trial in the US at

Q4 2015, expecting final data that include

safety and efficacy, by mid of 2016.


We become fat because we do not burn enough calories, yet consume extra food. Enhanced

thermogenesis (=heat production) can correct this imbalance. Thermogenesis in large

animals is different than that of small rodents and Raziel carefully verified that its drug acts

in small and large mammals as well. Raziel’s novel drug is able to convert energy-storing

white-adipose-tissue (WAT) into energy-burning brown-like adipose tissue, as evident by

histological, cellular and molecular studies. Moreover, the physiological outcome of this

tissue-remodelling is an outstanding local thermogenesis as clearly demonstrated in human-

size pigs. This thermogenesis lasts for several months following a single treatment, with the

ensuing ~30-50% reduction in s.c. fat at the treated site. The molecular target of Raziel

proprietary drug was also identified and is part of Raziel IP.

Company Name: Raziel Therapeutics LTD

Contact Details

Address: Hadassah Ein Kerem Jerusalem

Phone: 972 2 6250907

Fax: 972 2 6250901

Email:[email protected]

Website: Raziel-therapy.com


Name: Alon Bloomenfeld


Category: Pharmaceutical


25 | P a g e

Company Profile:

Taliaz Diagnostics develops genetic and

clinical-based predictive tools through

proprietary machine-learning algorithms to

guide clinicians in prescribing the right

medication for each individual patient.

The company's first tool is designed to

determine the right antidepressant

medication for each individual suffering from

depression. This tool includes a tissue

collection kit, a chip for DNA sequencing of

specific genomic regions, and algorithms

which analyze the unique genetic and clinical

information collected from each patient. The

tool ultimately generates a simple report

which guides the physician to prescribe the

correct treatment.


Our core technology is based on a proprietary predictive algorithm using the patient's DNA

sequencing to analyze 180 distinct genetic alterations through a simple non-invasive test

which yields results within 24 hours. The tool provides an objective match of the specific

drug with the most efficiency and least adverse effects for the individual patient.

Our diagnostic chip identifies the patient’s relevant genetic variations which together with

selected clinical features are uploaded to the cloud where our in-house big data and

developed machine learning algorithms analyzes the data. The algorithms ultimately predict

the right medication most suited for the individual patient.

Company Name: Taliaz Diagnostics Ltd.

Contact Details

Address: 2 Prof. Yehezkel Kaufmann St.,

Tel Aviv-Yafo, Israel

Phone: +972-(0)53-822-3951

Fax: +972-(0)77-335-2506


Website: www.taliazdiagnostics.com


Name: Dr. Dekel Taliaz, PhD


Category: Diagnostics

26 | P a g e

Company Profile:

VBL Therapeutics [NASDAQ:VBLT] is a late-stage

clinical biopharmaceutical company focused on

developing game-changing, innovative anti-

cancer therapies. Our lead oncology product, VB-

111, is a first-in-class, targeted anti-cancer gene-

therapy agent that is positioned to treat a wide

range of solid tumors. VB-111 is conveniently

administered as an IV infusion once every two

months. It has demonstrated safety in >170

cancer patients and efficacy signals in an `all

comers` Ph1 trial as well as in three tumor-

specific Ph2 studies. The mechanism of VB-111

combines blockade of tumor vasculature with an

anti-tumor immune response. This mechanism

retains activity regardless of baseline tumor

mutations or the identity of the pro-angiogenic factors secreted by the tumor. VB-111 is

currently being studied in the GLOBE Ph3 pivotal trial for Recurrent Glioblastoma (rGBM);

the trial is being conducted under an FDA Special Protocol Assessment (SPA), Fast track and

Orphan designation. Based on interactions with the FDA, we believe the current trial, if

successful, will support a Biologics License Application (BLA) in 2018. VB-111 is protected by

an issued composition-of-matter US patent, which extends to 2033, before any extensions.


VBL’s innovative, proprietary Vascular Targeting System (VTS™) platform technology

enables systemic administration of gene therapy to either destroy or promote angiogenic

blood vessels. VTS is both tissue and condition-specific, allowing for targeted and limited

gene expression in endothelial cells. For oncology applications, the transgene selected is

designed to destroy angiogenic blood vessels that feed solid tumors. For other potential

applications, such as ischemia, a different transgene can be selected that is designed to

promote the development of angiogenic blood vessels. Our Lecinoxoids platform technology

comprises a family of orally-administered small molecules designed to modulate the body’s

inflammatory response. Through inhibition of Toll-like Receptors and monocyte migration,

these safe oral molecules have the potential to treat conditions such as Atherosclerosis,

NASH and renal Fibrosis.

Company Strategy:

VBL has developed a diversified portfolio which includes both gene-therapy biologics and

anti-inflammatory small molecules. As we stay focused on oncology, we intend to pursue

regulatory approval for VB-111 in rGBM and continue development of VB-111 in Ovarian

Cancer. The company is seeking a strategic partner/s that will collaborate with VBL to fully

realize the potential of the VB-111 unique and innovative opportunity for multiple solid

tumors. We seek to out-license our non-oncology assets to support further development

and growth.

Company Name:

VBL Therapeutics [NASDAQ:VBLT]

Contact Details:

6 Jonathan Netanyahu St.

Or Yehuda, 60376 Israel


Website: www.vblrx.com

Exhibition Representatives:

Erez Feige, Ph.D., M.B.A.

VP Business Operations

Eyal Breitbart, Ph.D.

VP Research and Operations

Category: Biopharmaceutical

http://www.vblrx.com/

27 | P a g e

NOTES

28 | P a g e

NOTES

Government of Israel

Economic Missionto the West Coast

www.Innovationisrael.org.il

Israeli Life Science Industry: A Source of InnovationIsraeli Pavilion Booth 2205, June 6-9, 2016

Documents

Israeli Life Science Industry Catalog